As rumors of rescheduling grow more prominent, concerns about big pharma's potential control over the industry are escalating. We invited Dr. Matt Moore back for a third time to shed light on the challenges and opportunities in the development and research of cannabinoid and psychedelic drugs.  For those unfamiliar with Dr. Moore, he is an accomplished scientist with extensive experience in the pharmaceutical, cannabis, and psychedelic industries, adept at managing projects from pre-clinical stages to post-approval." This week, we sit down with Dr. Matthew Moore to discuss.Does Big Pharma benefit from a rescheduling of Cannabis?Cannabinoid Clinical Trials, challenges, and opportunities Brian Johnson and Medicine 3.0#ReschuedlingCannabis #clinicaltrials #personalizedmedicine Follow us: Our Links. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. 8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain  The Dime is a top 5% most shared  global podcast  The Dime is a top 50 Cannabis Podcast  Sign up for our playbook here: 

Are Drugs Bad, The Future Cannabinoids as a Medicine 3.0 ft. Dr. Matthew Moore

Bryan and Kellan are curious learners, who explore the creative strategies of entrepreneurs pioneering the cannabis industry, projected to reach a $100 billion valuation by 2023. Each week, we dive into guests' journeys, from CEOs of publicly traded giants and world-renowned scientists to underground legacy growers shaping the industry. Discover how they found their place in Cannabis, their original business plans, and the pivots and perseverance needed to navigate cannabis-specific challenges. Join us to uncover the crucial lessons learned from these diverse and rich entrepreneurial experiences in the cannabis world.

Business

Investing

Careers

Management & Marketing

Business News

Shopping

Science

Management

Entrepreneurship

Chemistry

New York's Cannabis Program can only be described one way: Broken.  Despite lessons learned from other states and a goal to help those previously harmed, the program has faced significant financial and operational challenges, falling short of its intended success. With government officials labeling the rollout a disaster and promising an overhaul, the extent of the program's issues is clear. Were these problems evident from the start, and how can they be fixed? We sat down with Neil Kaufman to break it all down and discuss the following:Where everything went wrongWhat Neil would do to fix itThe two-tier system and investment issues  About Neil Kaufman: Neil M. Kaufman is the managing member of Kaufman McGowan PLLC, Long Island’s Corporate & Securities Law Firm ™ and Corporate & Securities Counsel to the Cannabis Industry™. He is one of the leading corporate cannabis lawyers in New York and the USA and a fixture of the New York and Long Island corporate and securities legal community. Mr. Kaufman represents emerging growth, middle market and public companies and investment firms in their corporate, securities, financing, borrowing, merger & acquisition and other legal matters. Mr. Kaufman is particularly well known for advising clients with respect to SEC regulation, public offerings, private placements and mergers & acquisitions, as well as all types of commercial contracts. He is a frequent speaker on corporate, securities and cannabis law topics, and is an approved Vistage speaker on mergers & acquisitions. Guest Linkshttps://www.linkedin.com/in/neilmkaufman/https://kaufmanmcgowan.com/https://x.com/NeilMKaufmanFollow us: Our Links. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. 8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain  The Dime is a top 5% most shared  global podcast The Dime is a top 50 Cannabis Podcast Sign up for our playbook here: 

New York's Broken Cannabis Program: What Happened and How to Fix It ft. Neil Kaufman

Public companies dominate the headlines for the cannabis industry, but a few private beasts operate in plain sight. Motif Labs is one of them. Their deep focus on profitability and data at every step is why they have built such a deeply rooted and successful organizational philosophy. This week, we sit down with Mario Naric to discuss:How he builds process efficiency at every stepWhat understanding the data really meansWhen to bring services in-houseMario Naric, CEO & Founder of Motif Labs Mario Naric is the Founder & CEO of Motif Labs, a leading brand house shaping Canada's cannabis 2.0 market with a portfolio of iconic brands, including BOXHOT (#1 vape brand in Canada), DEBUNK, and  Rizzlers. With an unwavering passion for creating exceptional products and a background in chemical engineering, Mario has grown Motif Labs into the retailer's brand of choice, solidifying its position as a leader in Canada's 2.0 cannabis market. Mario's cannabis journey began in 2017 when he founded Motif Labs with a vision to define high standards of excellence and to create products that leave a lasting impression. Mario has led Motif Labs to unparalleled success and profitability, holding top market share positions in vapes and infused pre-rolls. Mario's hands-on leadership style and youthful energy infuse a unique vitality into Motif Labs. Guided by his passion, the company continues to push boundaries, creating products that exceed consumer expectations. Mario is known for his approachable demeanor and genuine commitment to making a difference. Mario and his wife live in London, Ontario. Guest Links https://www.linkedin.com/company/motif-labshttps://www.instagram.com/motif.labs/Follow us: Our Links. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. 8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain  The Dime is a top 5% most shared  global podcast The Dime is a top 50 Cannabis Podcast Sign up for our playbook here: 

Building a Private Juggernaut: Efficiency at Every Step with Mario Naric

Pricing and promotion in the retail business may seem closely linked but are fundamentally different. Understanding the intention behind a promotion across the organization is a critical yet often overlooked element in the cannabis industry. Using pricing as a tool to drive sales can have unintended consequences.  For example, if a customer typically purchases one product every 30 days but buys two products when offered at a lower price, they might not return for 60 days.  Did leveraging the price as a tool for additional sales work as intended? This week, we dive into the intricacies of cannabis retail, exploring all components of the system to understand what is needed to achieve profitability. Join us as Krista Raymer discusses how to put the pieces of the puzzle together for a successful retail strategy, covering topics such as:The difference between pricing and promotionInternal alignment on promotional strategiesThe potential pitfalls of using price to drive salesStrategy for long-term profitability in cannabis retailAbout Vetrina Group Create Cannabis Retail Experts. It’s been our mission since day one. We understand that unlocking success in cannabis retail is no easy feat. It takes dedication, hard work, and a deep understanding of what drives your consumers. By understanding what your consumers want and utilizing data-driven strategies, you can confidently execute innovative plans that lead to greater profitability. The Cannabis industry can be difficult, but we know retail can be strategic, planned, and successful when informed by data and experience. Guest Linkshttps://www.vetrinagroup.com/https://www.linkedin.com/in/krista-raymer/https://x.com/k_raymerhttps://x.com/vetrinagrouphttps://www.youtube.com/channel/UCAJkvtzo2RYpg0DnNITm8iQFollow us: Our Links. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. 8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain  The Dime is a top 5% most shared  global podcast The Dime is a top 50 Cannabis Podcast Sign up for our playbook here: 

Krista Raymer: Pricing, Promotion & Strategy Tips for Profitable Cannabis Retail

Synthesis, a process that may sound complex, is actually quite common in our daily lives. From the production of everyday items like Advil, organic milk, citric acid, to the creation of vitamins A and D, and multivitamins, synthesis is a key player. Why does this realization often provoke a negative reaction?  Perhaps it's because there's a desire for clean, safe, and consistent natural products, especially when they originate from plants. Surprisingly, synthesis enhances our ability to deliver such products. This week, we're joined by Shane Johnson to delve into the following topics: How minors are manufactured, synthetic vs. biosynthetic  Upcoming Minors to keep an eye on  Novel APIs & AnalogsAbout Dr. Shane Johnson Dr. Shane Johnson’s career has focused principally on offering strategic business advisory services to companies in the biotechnology and healthcare sectors. His work has included guiding regulatory strategy, product portfolio assessment and valuations, and product development and launch strategies for companies including Biogen Idec, Amgen, and Genentech.  Shane was a Principal at Hamilton BioVentures (a Life Science venture capital firm), an Engagement Manager at L.E.K. Consulting (an international strategy consulting firm), and held operational roles in several early stage companies. For the past 4 years, Shane’s work has been focused on the cannabis and cannabinoid science space, and he has developed a strong working knowledge of clinical opportunities in the sector.  He is currently on the Board of Directors of several cannabis-related companies, and is a co-founder of one of Nevada’s leading cultivators and producers of premium cannabis products including a patented lozenge. Shane holds a B.A. in Studio Art and a B.S. in Neuroscience (with honors) from Brown University, an M.D. from the Stanford University School of Medicine, and is a Fulbright Scholar. Guest Links https://www.baymedica.com/https://www.linkedin.com/in/shanejohnson3/https://www.youtube.com/channel/UC-XRZ0FMzcWgFL_mqdAOPRwhttps://twitter.com/BayMedicaFollow us: Our Links. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. 8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain  The Dime is a top 5% most shared  global podcast The Dime is a top 50 Cannabis Podcast Sign up for our playbook here: 

How Minor Cannabinoids are Made: Synthetic vs Biosynthetic ft. Shane Johnson

The economic impact of Hop Latent Viroid on cannabis cultivation remains a significant concern, costing the industry millions annually. In our latest episode, we dive into proactive measures to combat this threat with Dr. Tassa Saldi.  Affecting ~80% of cultivators, Dr. Saldi sheds light on the necessity of proactively testing. While some may question the need for proactive testing, likening it to insurance, the truth is stark: overlooking this crucial step could result in catastrophic consequences for your crops and business. Join us as we explore:The nuances of Hop Latent ViroidStrategies for proactive testingAssessing the value of a mother plantIdentifying other pathogens demanding attention in cannabis cultivationGuest Links: https://tumigenomics.myshopify.com/ https://www.linkedin.com/in/tassa-saldi-phd-03174a179/ https://twitter.com/tumigenomics https://www.instagram.com/tumigenomics/ Follow us: Our Links. At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry. 8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain  The Dime is a top 5% most shared  global podcast The Dime is a top 50 Cannabis Podcast Sign up for our playbook here: 

Are Drugs Bad, The Future Cannabinoids as a Medicine 3.0 ft. Dr. Matthew Moore

Download our free app to listen on your phone